首付款2亿美元!恒瑞授权交易再下一城:在研新药签单默沙东

澎湃新闻
26 Mar

虽然PD-1肿瘤药出海美国一波三折,但恒瑞医药通过授权交易“借船出海”的步伐还在继续。3月25日晚间,江苏恒瑞医药股份有限公司(恒瑞医药,600276)公告称,与默沙东达成协议,将恒瑞的脂蛋白(a)(以下简称“Lp(a)”)口服小分子项目(包括名为HRS-5346的先导化合物)有偿许可给默沙东。默沙东将获得HRS-5346在大中华地区以外的全球范围内开发、生产和商业化的独家权利。这份合作协议预计...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10